COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects

Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study

(2015) Xiao Hu et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Immunogenicity evaluation strategy for a second-generation therapeutic, PEG-IFN-β-1a

(2015) Joleen T White et al.   Bioanalysis

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE

(2014) Bernd C Kieseier et al.   Multiple Sclerosis Journal

Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents

(2012) Ricardo P Garay et al.   Expert Opinion on Drug Delivery

PEGylation of Interferon-β-1a

(2011) Bernd C. Kieseier et al.   CNS DRUGS

A Novel PEGylated Interferon Beta-1a for Multiple Sclerosis: Safety, Pharmacology, and Biology

(2011) Xiao Hu et al.   JOURNAL OF CLINICAL PHARMACOLOGY